TrialRMD open2023

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

Ines Colmegna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.